Go Pro

West Pharmaceutical Services (WST) Competitors

West Pharmaceutical Services logo
$352.94 -0.83 (-0.23%)
As of 08/21/2026 03:58 PM Eastern

WST vs. CHE, EHC, MDLN, ALC, and SOLV

Should you buy West Pharmaceutical Services stock or one of its competitors? West Pharmaceutical Services's main competitors and comparable companies include Chemed (CHE), Encompass Health (EHC), Medline (MDLN), Alcon (ALC), and Solventum (SOLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does West Pharmaceutical Services compare to Chemed?

West Pharmaceutical Services (NYSE:WST) and Chemed (NYSE:CHE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

West Pharmaceutical Services has a net margin of 16.98% compared to Chemed's net margin of 10.60%. Chemed's return on equity of 31.77% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
Chemed 10.60%31.77%18.90%

West Pharmaceutical Services has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19
Chemed$2.53B2.80$265.24M$19.9127.19

West Pharmaceutical Services presently has a consensus price target of $368.08, suggesting a potential upside of 4.29%. Chemed has a consensus price target of $530.75, suggesting a potential downside of 1.95%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, research analysts plainly believe West Pharmaceutical Services is more favorable than Chemed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87
Chemed
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.17

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 3.3% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. West Pharmaceutical Services pays out 11.3% of its earnings in the form of a dividend. Chemed pays out 14.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years. Chemed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, West Pharmaceutical Services had 12 more articles in the media than Chemed. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 4 mentions for Chemed. Chemed's average media sentiment score of 1.58 beat West Pharmaceutical Services' score of 1.57 indicating that Chemed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Chemed
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

West Pharmaceutical Services has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

West Pharmaceutical Services beats Chemed on 12 of the 20 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Encompass Health?

West Pharmaceutical Services (NYSE:WST) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

West Pharmaceutical Services has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Encompass Health had 2 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 18 mentions for Encompass Health and 16 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.57 beat Encompass Health's score of 1.19 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Encompass Health
14 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 1.8% of Encompass Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.6%. West Pharmaceutical Services pays out 11.3% of its earnings in the form of a dividend. Encompass Health pays out 12.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has raised its dividend for 2 consecutive years. Encompass Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

West Pharmaceutical Services has a net margin of 16.98% compared to Encompass Health's net margin of 10.01%. West Pharmaceutical Services' return on equity of 20.11% beat Encompass Health's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
Encompass Health 10.01%18.08%8.22%

West Pharmaceutical Services currently has a consensus target price of $368.08, suggesting a potential upside of 4.29%. Encompass Health has a consensus target price of $148.71, suggesting a potential upside of 23.68%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts plainly believe Encompass Health is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87
Encompass Health
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

Encompass Health has higher revenue and earnings than West Pharmaceutical Services. Encompass Health is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19
Encompass Health$5.94B2.00$566.20M$6.1419.58

Summary

West Pharmaceutical Services beats Encompass Health on 10 of the 19 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Medline?

Medline (NASDAQ:MDLN) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

West Pharmaceutical Services has a net margin of 16.98% compared to Medline's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
MedlineN/A N/A N/A
West Pharmaceutical Services 16.98%20.11%14.83%

Medline currently has a consensus target price of $47.42, suggesting a potential upside of 38.42%. West Pharmaceutical Services has a consensus target price of $368.08, suggesting a potential upside of 4.29%. Given Medline's higher probable upside, equities research analysts clearly believe Medline is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87

In the previous week, West Pharmaceutical Services had 1 more articles in the media than Medline. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 15 mentions for Medline. West Pharmaceutical Services' average media sentiment score of 1.57 beat Medline's score of 0.15 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
4 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Medline has higher revenue and earnings than West Pharmaceutical Services. Medline is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$29.94B1.50$1.16B$0.7943.37
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

West Pharmaceutical Services beats Medline on 10 of the 16 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Alcon?

West Pharmaceutical Services (NYSE:WST) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

West Pharmaceutical Services has a net margin of 16.98% compared to Alcon's net margin of 5.92%. West Pharmaceutical Services' return on equity of 20.11% beat Alcon's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
Alcon 5.92%7.29%5.09%

West Pharmaceutical Services presently has a consensus price target of $368.08, indicating a potential upside of 4.29%. Alcon has a consensus price target of $84.96, indicating a potential upside of 15.46%. Given Alcon's higher possible upside, analysts plainly believe Alcon is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63

West Pharmaceutical Services has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Alcon has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, West Pharmaceutical Services had 14 more articles in the media than Alcon. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 2 mentions for Alcon. West Pharmaceutical Services' average media sentiment score of 1.57 beat Alcon's score of 0.42 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Alcon
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 53.9% of Alcon shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 1.5% of Alcon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alcon has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19
Alcon$10.40B3.50$980M$1.3156.18

Summary

West Pharmaceutical Services beats Alcon on 10 of the 15 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Solventum?

Solventum (NYSE:SOLV) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Solventum has higher revenue and earnings than West Pharmaceutical Services. Solventum is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.83$1.56B$8.1810.96
West Pharmaceutical Services$3.07B8.08$493.70M$7.8145.19

Solventum has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Solventum has a net margin of 17.26% compared to West Pharmaceutical Services' net margin of 16.98%. Solventum's return on equity of 25.09% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum17.26% 25.09% 8.78%
West Pharmaceutical Services 16.98%20.11%14.83%

Solventum presently has a consensus target price of $91.64, indicating a potential upside of 2.23%. West Pharmaceutical Services has a consensus target price of $368.08, indicating a potential upside of 4.29%. Given West Pharmaceutical Services' stronger consensus rating and higher possible upside, analysts plainly believe West Pharmaceutical Services is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
4 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.54
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87

In the previous week, West Pharmaceutical Services had 12 more articles in the media than Solventum. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 4 mentions for Solventum. West Pharmaceutical Services' average media sentiment score of 1.57 beat Solventum's score of 0.91 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
16 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

West Pharmaceutical Services beats Solventum on 12 of the 17 factors compared between the two stocks.

Get West Pharmaceutical Services News Delivered to You Automatically

Sign up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WST vs. The Competition

MetricWest Pharmaceutical ServicesHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$24.85B$6.02B$7.37B$24.30B
Dividend Yield0.25%1.74%2.53%3.70%
P/E Ratio45.1926.67272.6030.31
Price / Sales8.0871.61624.3319.95
Price / Cash36.2633.2478.6232.49
Price / Book8.316.2313.056.77
Net Income$493.70M$150.07M$3.47B$1.07B
7 Day Performance1.15%0.69%2.09%-0.65%
1 Month Performance-0.65%8.91%6.64%3.38%
1 Year Performance42.56%8.07%25.02%14.90%

West Pharmaceutical Services Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WST
West Pharmaceutical Services
4.0722 of 5 stars
$352.94
-0.2%
$368.08
+4.3%
+42.6%$24.85B$3.07B45.1910,800
CHE
Chemed
4.052 of 5 stars
$524.60
-1.6%
$530.75
+1.2%
+17.7%$6.96B$2.53B26.3515,811
EHC
Encompass Health
4.8638 of 5 stars
$121.94
-1.3%
$148.71
+22.0%
-2.1%$12.19B$5.94B19.8642,000
MDLN
Medline
3.8358 of 5 stars
$34.88
-2.4%
$47.42
+36.0%
N/A$46.99B$28.43B44.1545,000
ALC
Alcon
3.1978 of 5 stars
$72.50
-2.4%
$84.63
+16.7%
-10.3%$36.73B$10.40B55.3425,942

Related Companies and Tools


This page (NYSE:WST) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners